Skip to main content
Top
Published in: Osteoporosis International 9/2006

01-09-2006 | Original Article

Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year

Authors: E. D. Newman, C. K. Matzko, T. P. Olenginski, J. L. Perruquet, T. M. Harrington, G. Maloney-Saxon, T. Culp, G. C. Wood

Published in: Osteoporosis International | Issue 9/2006

Login to get access

Abstract

Introduction

Patients who take chronic glucocorticoids (GC) are at increased risk of osteoporosis and fracture. Only a minority of patients who take chronic GC receive optimal osteoporosis prevention, diagnosis, and/or treatment.

Methods

An organized program of care—GIOP (Glucocorticoid-Induced Osteoporosis Program)—was designed and implemented. The program goals were to identify patients at risk of fracture, provide education, redesign and implement new pathways of care, and monitor outcomes. Two hundred chronic GC users were seen at baseline, and follow-up visits scheduled at 6 months and 1 year.

Results

Patient retention of knowledge, frequent exercise, and 25-OH Vitamin D levels all significantly improved at 1 year. A significant decrease in GC dose was seen. In terms of adherence, 91% of patients considered at high risk were taking a bisphosphonate or teriparatide at 1 year, and 96% of patients overall were adherent to their prescribed regimen of calcium, vitamin D, and prescription treatment (if indicated). Bone density at the spine and total hip increased significantly.

Conclusions

GIOP is the first organized program of care for patients who take chronic GC that has demonstrated a clinically significant improvement in outcome. The program’s design can be adapted and used by other health systems and organizations.
Literature
1.
go back to reference Saag KG (2003) Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin N Am 32:135–157CrossRef Saag KG (2003) Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin N Am 32:135–157CrossRef
2.
go back to reference Cohen D, Adachi JD (2004) The treatment of glucocorticoid-induced osteoporosis. J Steroid Biochem Mol Biol 88:337–349PubMedCrossRef Cohen D, Adachi JD (2004) The treatment of glucocorticoid-induced osteoporosis. J Steroid Biochem Mol Biol 88:337–349PubMedCrossRef
3.
go back to reference American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 44:1496–1503CrossRef American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 44:1496–1503CrossRef
4.
go back to reference Brown JP, Josse RG (2002) 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167(10 Suppl):S1–S30PubMed Brown JP, Josse RG (2002) 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167(10 Suppl):S1–S30PubMed
5.
go back to reference Eastell R, Reid DM, Compston J et al (1998) A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 244:271–292PubMedCrossRef Eastell R, Reid DM, Compston J et al (1998) A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 244:271–292PubMedCrossRef
6.
go back to reference Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J (2002) Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis. Arthritis Rheum 46:3136–3142PubMedCrossRef Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J (2002) Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis. Arthritis Rheum 46:3136–3142PubMedCrossRef
7.
go back to reference Blalock SJ, Norton LL, Patel RA, Dooley MA (2005) Patient knowledge, beliefs, and behavior concerning the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 53:732–739PubMedCrossRef Blalock SJ, Norton LL, Patel RA, Dooley MA (2005) Patient knowledge, beliefs, and behavior concerning the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 53:732–739PubMedCrossRef
8.
go back to reference Naunton M, Peterson GM, Jones G, Griffin GM, Bleasel MD (2004) Multifaceted educational program increase prescribing of preventive medication for corticosteroid induced osteoporosis. J Rheumatol 31:550–556PubMed Naunton M, Peterson GM, Jones G, Griffin GM, Bleasel MD (2004) Multifaceted educational program increase prescribing of preventive medication for corticosteroid induced osteoporosis. J Rheumatol 31:550–556PubMed
9.
go back to reference Solomon DH, Katz JN, La Tourette AM, Coblyn JS (2004) Multifaceted intervention to improve rheumatologists’ management of glucocorticoid-induced osteoporosis: a randomized controlled trial. Arthritis Rheum 51:383–387PubMedCrossRef Solomon DH, Katz JN, La Tourette AM, Coblyn JS (2004) Multifaceted intervention to improve rheumatologists’ management of glucocorticoid-induced osteoporosis: a randomized controlled trial. Arthritis Rheum 51:383–387PubMedCrossRef
10.
go back to reference Newman ED, Ayoub WT, Starkey RH, Diehl JM, Wood GC (2003) Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int 14:146–151PubMed Newman ED, Ayoub WT, Starkey RH, Diehl JM, Wood GC (2003) Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int 14:146–151PubMed
11.
go back to reference Newman ED, Ayoub WT, Matzko CK, Wood C (2003) Glucocorticoid-induced osteoporosis-significant improvement in bisphosphonate use utilizing standardized consultative DXA reporting. Arthritis Rheum 48:S499 Newman ED, Ayoub WT, Matzko CK, Wood C (2003) Glucocorticoid-induced osteoporosis-significant improvement in bisphosphonate use utilizing standardized consultative DXA reporting. Arthritis Rheum 48:S499
12.
go back to reference Canalis E, Bilezikian JP, Angeli A, Giustina A (2004) Perspectives on glucocorticoid-induced osteoporosis. Bone 34:593–598PubMedCrossRef Canalis E, Bilezikian JP, Angeli A, Giustina A (2004) Perspectives on glucocorticoid-induced osteoporosis. Bone 34:593–598PubMedCrossRef
13.
go back to reference Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMedCrossRef Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMedCrossRef
15.
go back to reference Homik JJ, Cranney A, Shea BJ et al (2005) Calcium and vitamin D for corticosteroid-induced osteoporosis (Cochrane Review) (2005) In: The cochrane library, Issue 4. Wiley, Chichester, UK Homik JJ, Cranney A, Shea BJ et al (2005) Calcium and vitamin D for corticosteroid-induced osteoporosis (Cochrane Review) (2005) In: The cochrane library, Issue 4. Wiley, Chichester, UK
16.
go back to reference Lane NE (2001) An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 27:235–253PubMedCrossRef Lane NE (2001) An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 27:235–253PubMedCrossRef
17.
go back to reference Reid IR (2000) Glucocorticoid-induced osteoporosis. Baillieres Clin Endocrinol Metab 14:279–298CrossRef Reid IR (2000) Glucocorticoid-induced osteoporosis. Baillieres Clin Endocrinol Metab 14:279–298CrossRef
18.
19.
go back to reference Adachi JD, Saag KG, Delmas PD et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids -a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211CrossRef Adachi JD, Saag KG, Delmas PD et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids -a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211CrossRef
20.
go back to reference Cohen S, Levy RM, Keller M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss -a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Arthritis Rheum 42:2309–2318PubMedCrossRef Cohen S, Levy RM, Keller M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss -a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Arthritis Rheum 42:2309–2318PubMedCrossRef
21.
go back to reference Lane NE, Sanchez S, Modin G et al (2000) Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled trial. J Bone Miner Res 15:944–951PubMedCrossRef Lane NE, Sanchez S, Modin G et al (2000) Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled trial. J Bone Miner Res 15:944–951PubMedCrossRef
22.
go back to reference Curtis JR, Westfall AO, Allison JJ et al (2005) Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 52:2486–2494CrossRef Curtis JR, Westfall AO, Allison JJ et al (2005) Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 52:2486–2494CrossRef
23.
go back to reference Harrington JT, Barash HL, Day S, Lease J (2005) Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthritis Rheum 53:198–204PubMedCrossRef Harrington JT, Barash HL, Day S, Lease J (2005) Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthritis Rheum 53:198–204PubMedCrossRef
Metadata
Title
Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year
Authors
E. D. Newman
C. K. Matzko
T. P. Olenginski
J. L. Perruquet
T. M. Harrington
G. Maloney-Saxon
T. Culp
G. C. Wood
Publication date
01-09-2006
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 9/2006
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-006-0149-3

Other articles of this Issue 9/2006

Osteoporosis International 9/2006 Go to the issue